Metastatic Melanoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Obesity associated with longer survival for men with metastatic melanoma - Science Daily



Obesity associated with longer survival for men with metastatic melanoma 
Science Daily
"The question is what underlying mechanism causes this advantage in obese men, and can we take advantage of it to improve outcomes in patients with melanoma?" McQuade said. "One hint may be the interaction between obesity, sex, and outcomes, which has ...

 


'Obesity Paradox' Offers Puzzling Survival Advantage in Men with Metastatic Melanoma - Curetoday.com



MedicalResearch.com (blog)
 
'Obesity Paradox' Offers Puzzling Survival Advantage in Men with Metastatic Melanoma 
Curetoday.com
While obesity is a known risk factor for more than a dozen types of cancer ? and poised to take over smoking as the leading preventable cause for the disease ? it may actually play a beneficial role in men with metastatic melanoma, according to a ...
Another Obesity Paradox: Obese Males Have Survival Advantage in Melanoma MedicalResearch.com (blog)

all 2 news articles » 


Intriguing: Better Survival in Melanoma in Obese Men - Medscape



Medscape
 
Intriguing: Better Survival in Melanoma in Obese Men 
Medscape
An analysis of nearly 2000 patients with metastatic melanoma who were treated with targeted therapies or immunotherapies has found that for patients who were classified as obese (ie, who had a body mass index [BMI] ?30), survival was significantly ...

 


Obesity Tied to Survival in Men With Melanoma - New York Times



New York Times
 
Obesity Tied to Survival in Men With Melanoma 
New York Times
Obese men treated for metastatic melanoma may survive longer than their normal-weight peers. Researchers did a retrospective analysis of 1,918 people, 1,155 of them men, under treatment for metastatic melanoma. The study is in Lancet Oncology. Compared ...
Obese Males May Have Melanoma Survival Advantage Genetic Engineering & Biotechnology News

all 4 news articles » 


Updated Findings Show OS Improvement With Binimetinib/Encorafenib in Melanoma as FDA Decision Pends - Targeted Oncology



Targeted Oncology
 
Updated Findings Show OS Improvement With Binimetinib/Encorafenib in Melanoma as FDA Decision Pends 
Targeted Oncology
?Many patients with BRAF-mutant melanoma still face significant challenges managing their disease, and there remains a substantial need for well-tolerated treatments that delay disease progression and improve overall survival,? Keith T. Flaherty, MD ...

 


Trending News Today: Obesity Linked to Higher Metastatic Melanoma Survival in Men - Specialty Pharmacy Times



Trending News Today: Obesity Linked to Higher Metastatic Melanoma Survival in Men 
Specialty Pharmacy Times
House GOP leaders are discussing repealing or delaying the Affordable Care Act employer mandate, according to The Hill. House Ways and Means Committee Chairman Kevin Brady (R-TX) said that he has discussed the topic with members of the committee and ...

 


Metastatic Melanoma Patients May Benefit From Beta Blockers - Cancer Network



Metastatic Melanoma Patients May Benefit From Beta Blockers 
Cancer Network
In studies developed by Kathleen Kokolus, MD, a postdoctoral fellow at Penn State, the researchers analyzed data from 195 metastatic melanoma patients who were treated with immunotherapy between 2000 and 2015. Among the 195 patients, 62 were also ...

 


Potential for Metastatic Melanoma Cure Seen in High CR Rate With Pembrolizumab - Oncology Nurse Advisor



Oncology Nurse Advisor
 
Potential for Metastatic Melanoma Cure Seen in High CR Rate With Pembrolizumab 
Oncology Nurse Advisor
Pembrolizumab leads to a durable complete response (CR) with low rates of relapse ? even 2 years after discontinuation ? and may cure a subset of patients with metastatic melanoma, according to a study published in the Journal of Clinical Oncology.1 ...

 


Weber Shares Insight on Future of Immunotherapy in Melanoma - OncLive



OncLive
 
Weber Shares Insight on Future of Immunotherapy in Melanoma 
OncLive
Weber: As we all know, immunotherapy for melanoma has revolutionized how we treat the disease. It started out with the best news, which was the long-term survival data that we had from the original randomized trial of ipilimumab plus nivolumab versus ...

 


Analysis Explores Continuing Anti-PD-1 Therapy Past Progression in Melanoma - OncLive



OncLive
 
Analysis Explores Continuing Anti-PD-1 Therapy Past Progression in Melanoma 
OncLive
Continuing treatment with PD-1 inhibitors after progression is not currently indicated for patients with melanoma, but researchers affiliated with the FDA have suggested there might be value in such a strategy. Investigators with the FDA's Center for ...